Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3297MR)

This product GTTS-WQ3297MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3297MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ339MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ12629MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ1767MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ10941MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ224MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ2868MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ11096MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ15076MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SSS-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW